(Q34425420)

2 August 2017

1 reference

title

Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration (English)

1 reference

2 August 2017

1 reference

Eugene W M Ng

1

1 reference

2 August 2017

Anthony P Adamis

series ordinal

2

1 reference

2 August 2017

publication date

1 June 2005

1 reference

Canadian Journal of Ophthalmology

2 August 2017

published in

1 reference

2 August 2017

volume

40

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

352-368

1 reference

Tumor angiogenesis: therapeutic implications

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

The biology of VEGF and its receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Clinical translation of angiogenesis inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Pegaptanib for neovascular age-related macular degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular permeability factor, an endothelial cell mitogen related to PDGF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor is a secreted angiogenic mitogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor: basic science and clinical progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Hypoxic regulation of vascular endothelial growth factor in retinal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor expression in choroidal neovascularization in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

VEGF164Is Proinflammatory in the Diabetic Retina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Molecular and biological properties of the vascular endothelial growth factor family of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

VEGF: a critical player in neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Macrophage depletion inhibits experimental choroidal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor rescues HN33 neural cells from death induced by serum withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular Endothelial Growth Factor Increases Release of Gelatinase A and Decreases Release of Tissue Inhibitor of Metalloproteinases by Microvascular Endothelial Cellsin Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Increased expression of angiogenic growth factors in age-related maculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Regulation of matrix biology by matrix metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Vascular Endothelial Growth Factor Induces Endothelial Fenestrations In Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Pigment epithelium-derived factor: a potent inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Stimulation of neovascularization by the anti-angiogenic factor PEDF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Systemically expressed soluble Tie2 inhibits intraocular neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Risks of intravitreous injection: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Corticosteroids in posterior segment disease: an update on new delivery systems and new indications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Developing aptamers into therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Quantitative image analysis of laser-induced choroidal neovascularization in rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. I. THE EFFECT OF DEXAMETHASONE IN THE NORMAL EYE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Exudative macular degeneration and intravitreal triamcinolone. A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Intravitreal triamcinolone acetonide and intraocular pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-4182%2805%2980078-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0008-4182(05)80078-X

1 reference

2 August 2017

1 reference